Overview
Glaucoma (green star) is the leading cause of irreversible blindness. It is estimated to affect more than 60 million people worldwide, with an increasing incidence in the elderly. Treatment is aimed at lowering intraocular pressure and may involve medication, laser intervention or surgery. In surgery, a small stent may be implanted in the eye to drain some of the aqueous humor and lower intraocular pressure.
HSLU in collaboration with Valsigna developed a systematic design methodology for a new eye stent that enables personalization to the patient and improves the safety and stability of the pressure adjustment. Read our article published in Micromachines https://www.mdpi.com/2072-666X/13/6/978
Valsigna is a company specialized in femto-second laser-based additive manufacturing of microstructures. HSLU contributed with its expertise in the development and simulation of microfluidic systems that interact with vascular sunconjunctival tissue after implantation.
